Which has higher earnings & valuation, NBTX or IMVT?

Nanobiotix has higher revenue and earnings than Immunovant. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $36.87M 46.77 -$27.11M N/A N/A Immunovant N/A N/A -$505.61M -$2.78 N/A

Is NBTX or IMVT more profitable?

Nanobiotix's return on equity of 0.00% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Immunovant N/A -65.66% -59.88%

Does the media favor NBTX or IMVT?

In the previous week, Immunovant had 1 more articles in the media than Nanobiotix. MarketBeat recorded 4 mentions for Immunovant and 3 mentions for Nanobiotix. Immunovant's average media sentiment score of 1.62 beat Nanobiotix's score of 0.74 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation and earnings, LNTH or NBTX?

Lantheus has higher revenue and earnings than Nanobiotix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.41 $233.56M $4.15 25.19 Nanobiotix $36.87M 46.77 -$27.11M N/A N/A

Is LNTH or NBTX more profitable?

Lantheus has a net margin of 18.05% compared to Nanobiotix's net margin of 0.00%. Lantheus' return on equity of 29.32% beat Nanobiotix's return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% Nanobiotix N/A N/A N/A

Does the media favor LNTH or NBTX?

In the previous week, Lantheus and Lantheus both had 3 articles in the media. Lantheus' average media sentiment score of 0.81 beat Nanobiotix's score of 0.74 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, KYMR or NBTX?

Nanobiotix has lower revenue, but higher earnings than Kymera Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kymera Therapeutics $39.21M 180.86 -$311.35M -$3.57 N/A Nanobiotix $36.87M 46.77 -$27.11M N/A N/A

Does the media refer more to KYMR or NBTX?

In the previous week, Kymera Therapeutics had 9 more articles in the media than Nanobiotix. MarketBeat recorded 12 mentions for Kymera Therapeutics and 3 mentions for Nanobiotix. Kymera Therapeutics' average media sentiment score of 0.77 beat Nanobiotix's score of 0.74 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, PTGX or NBTX?

Nanobiotix has lower revenue, but higher earnings than Protagonist Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Protagonist Therapeutics $46.02M 153.41 -$130.15M -$1.81 N/A Nanobiotix $36.87M 46.77 -$27.11M N/A N/A

Does the media favor PTGX or NBTX?

In the previous week, Protagonist Therapeutics had 6 more articles in the media than Nanobiotix. MarketBeat recorded 9 mentions for Protagonist Therapeutics and 3 mentions for Nanobiotix. Protagonist Therapeutics' average media sentiment score of 0.91 beat Nanobiotix's score of 0.74 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, NBTX or SYRE?

Nanobiotix has higher revenue and earnings than Spyre Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $36.87M 46.77 -$27.11M N/A N/A Spyre Therapeutics $890K 7,882.93 -$155.20M -$2.08 N/A

Is NBTX or SYRE more profitable?

Nanobiotix's return on equity of 0.00% beat Spyre Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Spyre Therapeutics N/A -42.88% -27.76%

Does the media prefer NBTX or SYRE?

In the previous week, Spyre Therapeutics had 1 more articles in the media than Nanobiotix. MarketBeat recorded 4 mentions for Spyre Therapeutics and 3 mentions for Nanobiotix. Spyre Therapeutics' average media sentiment score of 0.98 beat Nanobiotix's score of 0.74 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nanobiotix (NBTX) Competitors

$35.54 +0.21 (+0.59%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$35.52 -0.02 (-0.07%)

As of 06/12/2026 04:10 PM Eastern

Compare

NBTX vs. IMVT, LNTH, KYMR, PTGX, and SYRE

Should you buy Nanobiotix stock or one of its competitors? MarketBeat compares Nanobiotix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nanobiotix include Immunovant (IMVT), Lantheus (LNTH), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

How does Nanobiotix compare to Immunovant?

Nanobiotix (NASDAQ:NBTX) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Nanobiotix's return on equity of 0.00% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Immunovant	N/A	-65.66%	-59.88%

Nanobiotix has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by company insiders. Comparatively, 1.8% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Immunovant had 1 more articles in the media than Nanobiotix. MarketBeat recorded 4 mentions for Immunovant and 3 mentions for Nanobiotix. Immunovant's average media sentiment score of 1.62 beat Nanobiotix's score of 0.74 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Nanobiotix has higher revenue and earnings than Immunovant.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	46.77	-$27.11M	N/A	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

Nanobiotix currently has a consensus target price of $37.33, suggesting a potential upside of 5.05%. Immunovant has a consensus target price of $37.33, suggesting a potential upside of 11.05%. Given Immunovant's higher possible upside, analysts clearly believe Immunovant is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Summary

Nanobiotix and Immunovant tied by winning 6 of the 12 factors compared between the two stocks.

How does Nanobiotix compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Nanobiotix (NASDAQ:NBTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Lantheus currently has a consensus target price of $101.86, suggesting a potential downside of 2.55%. Nanobiotix has a consensus target price of $37.33, suggesting a potential upside of 5.05%. Given Nanobiotix's higher probable upside, analysts clearly believe Nanobiotix is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Lantheus has a net margin of 18.05% compared to Nanobiotix's net margin of 0.00%. Lantheus' return on equity of 29.32% beat Nanobiotix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Nanobiotix	N/A	N/A	N/A

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Lantheus has higher revenue and earnings than Nanobiotix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.41	$233.56M	$4.15	25.19
Nanobiotix	$36.87M	46.77	-$27.11M	N/A	N/A

Lantheus has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

In the previous week, Lantheus and Lantheus both had 3 articles in the media. Lantheus' average media sentiment score of 0.81 beat Nanobiotix's score of 0.74 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lantheus beats Nanobiotix on 9 of the 13 factors compared between the two stocks.

How does Nanobiotix compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Nanobiotix (NASDAQ:NBTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Nanobiotix has lower revenue, but higher earnings than Kymera Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	180.86	-$311.35M	-$3.57	N/A
Nanobiotix	$36.87M	46.77	-$27.11M	N/A	N/A

Kymera Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

38.8% of Nanobiotix shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Kymera Therapeutics had 9 more articles in the media than Nanobiotix. MarketBeat recorded 12 mentions for Kymera Therapeutics and 3 mentions for Nanobiotix. Kymera Therapeutics' average media sentiment score of 0.77 beat Nanobiotix's score of 0.74 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kymera Therapeutics currently has a consensus price target of $117.14, indicating a potential upside of 35.87%. Nanobiotix has a consensus price target of $37.33, indicating a potential upside of 5.05%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kymera Therapeutics is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nanobiotix has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Nanobiotix's return on equity of 0.00% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Nanobiotix	N/A	N/A	N/A

Summary

Kymera Therapeutics beats Nanobiotix on 10 of the 15 factors compared between the two stocks.

How does Nanobiotix compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Nanobiotix (NASDAQ:NBTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

In the previous week, Protagonist Therapeutics had 6 more articles in the media than Nanobiotix. MarketBeat recorded 9 mentions for Protagonist Therapeutics and 3 mentions for Nanobiotix. Protagonist Therapeutics' average media sentiment score of 0.91 beat Nanobiotix's score of 0.74 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Nanobiotix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Protagonist Therapeutics presently has a consensus price target of $115.21, suggesting a potential upside of 4.95%. Nanobiotix has a consensus price target of $37.33, suggesting a potential upside of 5.05%. Given Nanobiotix's higher probable upside, analysts plainly believe Nanobiotix is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nanobiotix has lower revenue, but higher earnings than Protagonist Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	153.41	-$130.15M	-$1.81	N/A
Nanobiotix	$36.87M	46.77	-$27.11M	N/A	N/A

Nanobiotix has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Nanobiotix's return on equity of 0.00% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Nanobiotix	N/A	N/A	N/A

Summary

Protagonist Therapeutics beats Nanobiotix on 10 of the 15 factors compared between the two stocks.

How does Nanobiotix compare to Spyre Therapeutics?

Nanobiotix (NASDAQ:NBTX) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Nanobiotix has higher revenue and earnings than Spyre Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	46.77	-$27.11M	N/A	N/A
Spyre Therapeutics	$890K	7,882.93	-$155.20M	-$2.08	N/A

Nanobiotix has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.05, suggesting that its stock price is 205% more volatile than the broader market.

Nanobiotix's return on equity of 0.00% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Spyre Therapeutics	N/A	-42.88%	-27.76%

Nanobiotix presently has a consensus price target of $37.33, suggesting a potential upside of 5.05%. Spyre Therapeutics has a consensus price target of $91.33, suggesting a potential upside of 13.05%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Spyre Therapeutics is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Spyre Therapeutics had 1 more articles in the media than Nanobiotix. MarketBeat recorded 4 mentions for Spyre Therapeutics and 3 mentions for Nanobiotix. Spyre Therapeutics' average media sentiment score of 0.98 beat Nanobiotix's score of 0.74 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Spyre Therapeutics beats Nanobiotix on 10 of the 14 factors compared between the two stocks.

Get Nanobiotix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBTX vs. The Competition

Export

Metric	Nanobiotix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.71B	$2.99B	$6.75B	$12.02B
Dividend Yield	N/A	1.76%	2.66%	5.61%
P/E Ratio	N/A	18.07	24.02	24.43
Price / Sales	46.77	302.43	510.75	109.73
Price / Cash	N/A	56.52	44.01	55.64
Price / Book	-18.04	3.99	10.66	6.79
Net Income	-$27.11M	$75.85M	$3.56B	$337.66M
7 Day Performance	0.23%	1.14%	0.87%	2.57%
1 Month Performance	-31.71%	-3.28%	0.25%	2.04%
1 Year Performance	590.10%	22.54%	25.22%	30.28%

Nanobiotix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBTX Nanobiotix	3.3947 of 5 stars	$35.54 +0.6%	$37.33 +5.0%	+517.0%	$1.71B	$36.87M	N/A	100	Short Interest Decrease Gap Down
IMVT Immunovant	3.0196 of 5 stars	$30.75 -6.4%	$37.33 +21.4%	+110.9%	$6.75B	N/A	N/A	120	Positive News
LNTH Lantheus	2.7058 of 5 stars	$97.66 +0.5%	$101.86 +4.3%	+30.4%	$6.47B	$1.55B	23.77	1,193
KYMR Kymera Therapeutics	2.3486 of 5 stars	$74.38 -5.2%	$118.10 +58.8%	+82.3%	$6.45B	$51.48M	N/A	170	News Coverage
PTGX Protagonist Therapeutics	1.5726 of 5 stars	$93.98 -1.0%	$115.21 +22.6%	+94.9%	$6.40B	$74.06M	N/A	120	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBTX) was last updated on 6/13/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nanobiotix (NBTX) Competitors

NBTX vs. IMVT, LNTH, KYMR, PTGX, and SYRE

How does Nanobiotix compare to Immunovant?

Summary

How does Nanobiotix compare to Lantheus?

Summary

How does Nanobiotix compare to Kymera Therapeutics?

Summary

How does Nanobiotix compare to Protagonist Therapeutics?

Summary

How does Nanobiotix compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX vs. The Competition

Nanobiotix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nanobiotix (NBTX) Competitors

NBTX vs. IMVT, LNTH, KYMR, PTGX, and SYRE

How does Nanobiotix compare to Immunovant?

Is NBTX or IMVT more profitable?

Which has more risk & volatility, NBTX or IMVT?

Do institutionals and insiders hold more shares of NBTX or IMVT?

Does the media favor NBTX or IMVT?

Which has higher earnings & valuation, NBTX or IMVT?

Do analysts prefer NBTX or IMVT?

Summary

How does Nanobiotix compare to Lantheus?

Do analysts prefer LNTH or NBTX?

Is LNTH or NBTX more profitable?

Do insiders & institutionals hold more shares of LNTH or NBTX?

Which has better valuation and earnings, LNTH or NBTX?

Which has more volatility and risk, LNTH or NBTX?

Does the media favor LNTH or NBTX?

Summary

How does Nanobiotix compare to Kymera Therapeutics?

Which has preferable valuation & earnings, KYMR or NBTX?

Which has more volatility and risk, KYMR or NBTX?

Do insiders and institutionals have more ownership in KYMR or NBTX?

Does the media refer more to KYMR or NBTX?

Do analysts recommend KYMR or NBTX?

Is KYMR or NBTX more profitable?

Summary

How does Nanobiotix compare to Protagonist Therapeutics?

Does the media favor PTGX or NBTX?

Which has more volatility & risk, PTGX or NBTX?

Do institutionals and insiders hold more shares of PTGX or NBTX?

Do analysts recommend PTGX or NBTX?

Which has preferable earnings & valuation, PTGX or NBTX?

Is PTGX or NBTX more profitable?

Summary

How does Nanobiotix compare to Spyre Therapeutics?

Do institutionals & insiders hold more shares of NBTX or SYRE?

Which has preferable earnings & valuation, NBTX or SYRE?

Which has more volatility and risk, NBTX or SYRE?

Is NBTX or SYRE more profitable?

Do analysts prefer NBTX or SYRE?

Does the media prefer NBTX or SYRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX vs. The Competition

Nanobiotix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools